IGF2BP1 and gastric cancer: IGF2BP1 recognizes METTL3-mediated m6A modification of APAF1-binding lncRNA (ABL), which enhances ABL stability and thus promotes gastric cancer proliferation and chemoresistance (Wang et al., 2022[260]).